AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced positive top-line results from three pivotal Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

Call Buying Activity in AbbVie (ABBV) Targets 3% Upside in Shares Into Mid-November Ahead Various Drug Trials -Susquehanna October 30, 2017 2:39 PM Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis StudiesOctober 26, 2017 8:06 AM